Published in final edited form as:

J Nat Prod. 2012 March 23; 75(3): 479–483. doi:10.1021/np200697j.

Antiproliferative Acetogenins from a *Uvaria* sp. from the Madagascar Dry Forest¹

Yumin Dai[†], Liva Harinantenaina[†], Peggy J. Brodie[†], Martin W. Callmender[‡], Richard Randrianaivo[‡], Stephan Rakotonandrasana[§], Etienne Rakotobe[§], Vincent E. Rasamison[§], Yongchun Shen[⊥], Karen TenDyke[⊥], Edward M. Suh[⊥], and David G. I. Kingston^{†,*}

[†]Department of Chemistry, M/C 0212, Virginia Tech, Blacksburg, VA 24061, United States

[‡]Missouri Botanical Garden, B.P 3391, Antananarivo 101, Madagascar

[§]Centre National d'Application des Recherches Pharmaceutiques, B.P 702, Antananarivo 101, Madagascar

[⊥]Next Generation Systems, Eisai Inc., 4 Corporate Drive, Andover, Massachusetts 01810

Abstract

Investigation of the endemic Madagascan plant *Uvaria* sp. for antiproliferative activity against the A2780 ovarian cancer cell line led to the isolation of two new acetogenins. The structures of these two compounds were elucidated based on analysis of their 1D and 2D NMR spectra, circular dichroism and mass spectrometric data, together with chemical modification. The two acetogenins display weak antiproliferative activity against the A2780 ovarian cancer, the A2058 melanoma, and the H522 lung cancer cell lines.

As part of our engagement in an International Cooperative Biodiversity Group (ICBG) program, we are focusing on searching for antiproliferative natural products from both tropical dry forests and rain forests in Madagascar. As a part of this research, an EtOH extract from the aerial parts of a *Uvaria* sp. (Annonaceae) from the dry forest of northern Madagascar exhibited weak anti-proliferative activity against the A2780 human ovarian cancer cell line, with an IC₅₀ value of 20 µg/mL. Compounds of the Annonaceae family are well-known for their broad range of bioactivity, including immuno-suppression, anti-malarial, insecticidal, anti-feedant, and antitumor activities.^{2–6} The genus *Uvaria* has been investigated extensively, with over 300 references in the chemical and biological literature, and the chemical constituents of *Uvaria* species have been summarized.^{7, 8} The genus *Uvaria* is also one of only seven of the 120 genera of the Annonaceae family known to produce acetogenins,⁹ and uvaricin, the first example of these compounds, was isolated from the roots of *Uvaria accuminata* Oliv. by Jolad et al. in 1982.¹⁰

Although the genus *Uvaria* has been well investigated, no work has been done on this new species. A total of seventeen *Uvaria* species are currently known in Madagascar, and eleven remain to be described.¹¹ This extract was thus selected for bioassay-guided fractionation to isolate its active components.

*Corresponding Author: To whom correspondence should be addressed: Tel: +1-540-231-6570. Fax: +1-540-231-3255. dkingston@vt.edu.

DEDICATION

Dedicated to Dr. Gordon M. Cragg, formerly Chief, Natural Products Branch, National Cancer Institute, Frederick, Maryland, for his pioneering work on the development of natural product anticancer agents.

Supporting Information

Figures S1 – S4 and ¹H and ¹³C NMR spectra of **1** and **2** are available free of charge via the Internet at <http://pubs.acs.org>.

The EtOH extract of the aerial parts of the *Uvaria* sp. was subjected to liquid-liquid partitioning to give an active CH₂Cl₂ fraction with an IC₅₀ value of 20 µg/mL. Bioassay-guided separation, including LH-20 size-exclusion, silica gel normal-phase and C18 reverse-phase chromatography, was used to obtain the two new acetogenins uvaricin A (**1**) and uvaricin B (**2**) with modest antiproliferative activity against A2780 ovarian cancer cells, with IC₅₀ values of 6.4 µM and 8.8 µM, respectively. Herein, we report the structural elucidation and antiproliferative properties of the two isolates.

Uvaricin A (**1**), [α]_D²¹ +23° (c 1.2, MeOH), was isolated as a white wax-like solid. The positive ion HRESIMS of uvaricin A revealed a quasi-molecular ion peak at *m/z* 623.4908 [M + H]⁺ and adduct ions at *m/z* 640.5147 [M + NH₄]⁺ and 645.4726 [M + Na]⁺, corresponding to a molecular formula of C₃₇H₆₆O₇. A carbonyl absorption at 1747 cm⁻¹ in its IR spectrum, UV absorption at 210 nm (MeOH), ¹H NMR signals at δ_H 6.98 (H-35), 4.98 (H-36) and 0.88 (H-34), and ¹³C NMR resonances at δ_C 174.2 (C-1), 149.1 (C-35), 134.6 (C-2), 77.6 (C-36), and 19.4 (C-37), were indicative of a methylated α,β -unsaturated γ -lactone ring (Table 1).^{12, 13} This was confirmed by three bond HMBC correlations observed between H-35 and C-1 and between H-35 and C-37, as well as two bond HMBC correlations between H-35 and C-2 and between H-36 and C-37 (Fig. S1a). Three OH functionalities in **1** were evident from the IR absorption at 3376 cm⁻¹, and the ¹³C NMR resonances at δ_C 74.3 (C-21), 72.1 (C-8) and 71.6 (C-12). The presence of a *bis*-THF ring system with two flanking OH groups was suggested by the four ¹³C NMR resonances at δ_C 83.5, 83.0, 82.8, and 82.5, which were correlated to the proton signals at δ_H 3.79–3.93 (5H) in the HMQC spectrum, as described for similar structures.¹⁴ The existence of the THF ring was confirmed by the HMBC correlations between C-13 and H-16. The one-bond ¹H-¹³C correlations detected in the HMQC spectrum, along with the observed multiple-bond ¹H-¹³C correlations in the HMBC spectrum, permitted the assignment of the carbon signals at δ_C 74.4 and 71.6 to the carbons adjacent to the THF rings at C-12 and C-21, respectively, with the proton signals at δ_H 3.39 and 3.87. A third OH group in the hydrocarbon chain was suggested by the resonances at δ_H 3.60 and δ_C 72.1.

The locations of the THF rings and the third OH group on the hydrocarbon chain were determined by analysis of 1D NMR, HMBC, HMQC, and COSY spectroscopic data, and confirmed by analysis of the EIMS fragmentation shown in Fig. S2a. In the vicinity of the THF moiety, the chemical shift at δ 22.2 in the ¹³C NMR spectrum was assigned to C-10 by the observation of an HMBC long-range correlation between H-12 (δ_H 3.87) and C-10 (δ_C 22.2). The third OH was assigned to C-8 by the presence of HMBC correlations between H-9 and C-10, and H-8 and C-9, as well as the COSY coupling of H-9 and H-8. The presence of an oxygen-bearing methine at C-8 was confirmed by the HMBC correlations between H-9 and C-7, H-8 and C-7, H-7 and C-6, H-4 and C-6, H-4 and C-3, H-3 and C-5, and H-3 and C-35, as well as a COSY cross-peak between H-4 and H-5. The number of carbons between the THF rings and the lactone ring was therefore restricted to ten.

The planar structure was further supported by the analysis of EIMS fragmentation. Intense fragment ions were observed at *m/z* 399, 347, 295, and 207. As shown in Fig. S2a, these fragmentations are consistent with those observed for similar acetogenins, and they fully support the assigned structure.¹⁵ In particular, the unusual loss of H₂O accompanied by H₂ has been observed before.¹⁶

The relative configurations around the *bis*-THF rings were determined by analysis of the ¹H NMR spectrum and comparison with literature data. In Fig. S3a, the chemical shifts at δ_H 3.39 (H-21) and 3.84 (H-20) indicated the *S** and *S** relative configurations, while the *S** and *R** relative configurations were deduced for C-12 and C-13 and for C-16 and C-17, due to the similarity of the chemical shift of H-12 (δ_H 3.87) and H-13 (δ_H 3.83), and of H-16 (δ_H

3.93) and H-17 (δ_{H} 3.91).^{17, 18} The methylene protons H-18 and H-19 were assigned to signals at δ_{H} 1.60 and 1.97 based on COSY correlations between H-20 and H-21, H-19 and H-20, and H-18 and H-17, combined with HMBC coupling between H-19 and C-17. The difference between these chemical shifts indicated a *trans* configuration for the C-17/C-20 THF ring.¹⁹ In the same manner, a *trans* configuration was assigned to the C-13/C-16 THF ring based on the divergent chemical shifts at δ_{H} 1.62 and 1.87 for H-14 and H-15.¹⁹ Thus, the relative configuration around the *bis*-THF rings was concluded to be *S**-*R**-*R**-*S**-*S**-*S** for C-12, C-13, C-16, C-17, C-20 and C-21. The absolute configuration of C-36 was determined by CD spectroscopic analysis. The negative $n-\pi^*$ Cotton effect ($\Delta\epsilon = -1.13$) at 238 nm and a positive $\pi-\pi^*$ Cotton effect ($\Delta\epsilon = 8.79$) at 208 nm, clearly indicated the *S* configuration at C-36 in the lactone ring.¹⁶ The absolute configurations of the OH groups adjacent to the THF rings were determined by Mosher ester methodology²⁰ using the (*R*)-MPA and (*S*)-MPA derivatives²¹ and the “in NMR tube” method.²² As shown in Fig. S4a, the $\Delta\delta_{\text{H}}$ ($= \delta_{\text{S}} - \delta_{\text{R}}$) was negative on both chain sides and positive along the THF rings, indicating *S* configurations at both C-12 and C-21.²³ The configuration of C-8 could not be determined due to the negative $\Delta\delta_{\text{H}}$ values displayed by both H-7 and H-9 on the hydrocarbon chain.

Uvaricin B (**2**), $[\alpha]_{\text{D}}^{21} +18^\circ$ (*c* 1.2, MeOH), was also isolated as a white wax-like solid. The positive ion HRESIMS of **2** revealed a quasi-molecular ion peak at m/z 623.4908 $[\text{M} + \text{H}]^+$ and adduct ions at m/z 640.5147 $[\text{M} + \text{NH}_4]^+$ and 645.4726 $[\text{M} + \text{Na}]^+$, corresponding to a molecular formula of $\text{C}_{37}\text{H}_{66}\text{O}_7$. The NMR, IR and UV data of compound **2** were very similar to those of compound **1**. As with compound **1**, absorptions typical of a methylated α,β -unsaturated γ -lactone ring in its IR and UV spectra and of a *bis*-THF ring system with two flanking OH groups in the ^1H and ^{13}C NMR spectra were observed (Table 1). These structures were supported by the long-range HMBC correlations shown in Fig. S1b. A third OH group was also present in the hydrocarbon chain, as indicated by NMR signals at δ_{H} 3.60 and δ_{C} 70.9.

The locations of the THF rings and of the third OH group on the hydrocarbon chain were determined by analysis of the 1D NMR, HMBC, HMQC, and COSY spectra, and confirmed by analysis of EI-MS fragmentations. The two diastereotopic protons (δ_{H} 2.37/2.51) were assigned to H_{2-3} based on HMBC correlations between H-3 and C-1, H-3 and C-2, and H-35 and C-3. The presence of an HMBC long-range coupling between a methylene carbon at δ_{C} 21.5 and H-3, as well as its connected proton (δ_{H} 1.65) and C-2, confirmed the assignment of this methylene carbon at C-4. The adjacent oxygen bearing carbon was located at C-5 by the presence of HMBC correlations between H-4 and C-5, and H-3 and C-5. The C-5 OH was confirmed by comparing the chemical shift of H-35 with those of other acetogenins of the same molecular formula and with OH groups at C-4, C-5, C-6, C-12 or C-15. As previously reported, the chemical shift of H-35 in C-5 hydroxylated acetogenins such as narumicin I and calamistrin F^{24, 25} is always more shielded (δ_{H} 7.05) than with C-4 hydroxylated acetogenins, such as bullatacin ($\delta_{\text{H-35}}$ 7.16) and squamotacin ($\delta_{\text{H-35}}$ 7.17).²⁶ Its chemical shift is however deshielded compared with the corresponding protons of acetogenins without an OH group near the lactone ring, such as the C-12 hydroxylated acetogenin, folianin B ($\delta_{\text{H-35}}$ 6.98)²⁷ and the C-15 hydroxylated acetogenin, guanaconetin-1 ($\delta_{\text{H-35}}$ 6.98).²⁸ Acetogenins with an OH at C-5 could be distinguished from C-6 hydroxylated acetogenins by their divergent chemical shift at H-3, albeit sharing similar $\delta_{\text{H-35}}$ values.²⁹

Analysis of the EIMS fragmentation supported the above structure. The fragment ions at m/z 155 and 135 are consistent with the conclusion that the third OH is connected to C-5, while the fragment ions at m/z 437, 367, 355, and 267 and their subsequent daughter ions indicated

that the *bis*-THF rings and the two flanking OH groups are located between C-14 and C-23 (Fig. S2b).

The relative configurations around the *bis*-THF rings were determined by examination of the data from proton NMR spectra and comparison to those in the literature. As shown in Fig. S3b, the ^1H NMR chemical shifts around the *bis*-THF rings for compound **2** were similar to those of compound **1**, and the relative configurations were therefore assigned as $S^*-R^*-R^*-S^*-S^*-S^*$ for C-14, C-15, C-17, C-18, C-22 and C-23. The CD spectrum of **2** revealed a negative $n-\pi^*$ Cotton effect ($\Delta\epsilon = -1.15$) at 238 nm and a positive $\pi-\pi^*$ Cotton effect ($\Delta\epsilon = 9.64$) at 208 nm, indicating an *S* configuration at the stereogenic center (C-36) in the lactone ring.¹⁶ The absolute configurations of the three secondary alcohols were determined by Mosher ester methodology in the same way as for **1**. As depicted in Fig. S4b, the $\Delta\delta_{\text{H}}$ ($= \delta_{\text{S}} - \delta_{\text{R}}$) is negative on the chain side and positive towards the THF rings, indicating the *S* configuration of both C-14 and C-23.²³ The positive values for H-3 and H-4 and negative values for H-6 to H-8 indicated an *S* configuration for C-5.

Uvaricin A (**1**) and B (**2**) were evaluated for antiproliferative activity against the A2780 ovarian cancer, the A2058 melanoma, and the H522 lung cancer cell lines (Table 2). Both compounds showed weak inhibition of all three cell lines, with IC_{50} values in the low micromolar range. Several hundred acetogenins have been identified from these plants, but not all of them have antiproliferative activity. According to previous studies of the structure-activity relationships of acetogenins, the relative configuration of the THF rings and the positions of the OH groups on the hydrocarbon chains have significant influence on their activities. The *threo-cis-threo-cis-erythro* configuration was described as the most potent subgroup of acetogenins with *bis*-THF rings;³⁰ as an example, rolliniastatin-1 has an IC_{50} value of $0.7 \times 10^{-7} \mu\text{M}$ against SW480 human colon cancer cells.³¹ In addition, the presence of two OH groups adjacent to the THF rings is necessary for potent inhibitory effects.³² The moderate cytotoxicity of uvaricins A and B can thus be explained by the stereochemistry of the *bis*-THF rings flanked by the two OH groups, whose configuration is different from that of rolliniastatin-1. The weak antiproliferative activity may also be due to the number and the location of the OH groups.^{32, 33}

EXPERIMENTAL SECTION

General Experimental Procedures

Optical rotations were recorded on a JASCO P-2000 polarimeter. UV and IR spectroscopic data were measured on a Shimadzu UV-1201 spectrophotometer and a MIDAC M-series FTIR spectrophotometer, respectively. CD spectra were obtained on a JASCO J-815 Circular Dichroism spectrometer. NMR spectra were recorded in CD_3OD or CDCl_3 on either JEOL Eclipse 500 or Bruker Avance 600 spectrometers. The chemical shifts are given in δ (ppm), and coupling constants (J) are reported in Hz. Mass spectra were obtained on an Agilent 6220 LC-TOF-MS in the positive ion mode; NH_4^+ adducts are commonly observed with this instrument. HPLC was performed on a Shimadzu LC-10AT instrument with a semipreparative C18 Varian Dynamax column ($5 \mu\text{m}$, $250 \times 10 \text{ mm}$).

Plant Material

The above-ground parts of *Uvaria* sp. were collected in July 2005. The plant was a liana with immature yellowish green fruit, and probably represents a new species still to be described.³⁴ The collection was made in dry degraded evergreen broadleaf forest near Betsimiranjana, in the Ambilobe region of Madagascar, at coordinates $13^\circ 02' 35''\text{S}$ $049^\circ 09' 15''\text{E}$. Voucher specimens have been deposited at the Parc Botanique and Zoologique de Tsimbazaza (TAN), at the Centre National d'Application des Recherches Pharmaceutiques in Antananarivo, Madagascar (CNARP), the Missouri Botanical Garden in

St. Louis, Missouri (MO), and the Muséum National d'Histoire Naturelle in Paris, France (P), voucher Stéphane Rakotonandrasana et al. 923.

Antiproliferative Bioassays

Antiproliferative activities were obtained at Virginia Polytechnic Institute and State University against the drug-sensitive A2780 human ovarian cancer cell line as previously described.³⁵ Antiproliferative activities against the A2058 melanoma and the H522 lung cancer cell lines were determined at Eisai Inc. by similar procedures to those used for the H460 cell line.³⁶

Extraction and Isolation

Dried aerial parts of *Uvaria sp.* (250 g) were ground in a hammer mill, then extracted with EtOH by percolation for 24 h at room temperature to give the crude extract MG 3352 (24.9 g), of which 6.9 g was shipped to Virginia Tech for bioassay-guided isolation against the A2780 cell line. A 1.0 g sample of MG 3352 (IC₅₀ 20.0 µg/mL) was suspended in aqueous MeOH (MeOH:H₂O 9:1, 100 mL), and extracted with hexane (3 × 100 mL portions). The aqueous layer was then diluted to 60% MeOH (v/v) with H₂O and extracted with CH₂Cl₂ (3 × 150 mL portions). The hexane fraction was evaporated in vacuo to leave 567 mg of material with IC₅₀ >20 µg/mL. The residue from the CH₂Cl₂ fraction (200 mg) had an IC₅₀ of 20 µg/mL, and the remaining aqueous MeOH fraction had an IC₅₀ >20 µg/mL. LH-20 size exclusion open column chromatography of the CH₂Cl₂ fraction was used to obtain four fractions, of which the most active fraction (106 mg) had an IC₅₀ of 6.9 µg/mL. This fraction was applied to a silica gel column eluted with a gradient of hexane:EtOAc, 9:1, 4:1, and 0:1 to give four fractions, of which the 100% EtOAc fraction (71.0 mg) was the most active (IC₅₀ 5.5 µg/mL). A C-18 open column was employed for further separation, eluted by 90% MeOH to give 8 fractions, and the most active one (IC₅₀ 4.3 µg/mL) was separated by C-18 HPLC with the solvent system MeOH:H₂O, 85:15 and a flow rate of 2 mL/min. This yielded two active compounds, with IC₅₀ values of 4.0 and 5.5 µg/mL, and with elution times of 28.3 and 35 min, respectively.

Uvaricin A (1): white wax-like solid; $[\alpha]_D^{21} +23$ (c 1.2, MeOH); UV (MeOH) $\lambda_{\max}$ (ε) 210 (2.60); IR $\nu_{\max}$ cm⁻¹: 3376, 2920, 1748, 1466, 1027 cm⁻¹. ¹H NMR (500 MHz, CDCl₃), and ¹³C NMR (125 MHz, CDCl₃), see Table 1; HRESIMS m/z 645.4726 [M + Na]⁺ (calcd for C₃₇H₆₆NaO₇, 645.4726).

Uvaricin B (2): white wax-like solid; $[\alpha]_D^{21} +18$ (c 1.2, MeOH); UV (MeOH) $\lambda_{\max}$ (ε) 210 (2.20); IR $\nu_{\max}$ cm⁻¹: 3449, 2923, 1753, 1460, 1024 cm⁻¹. ¹H NMR (500 MHz, CDCl₃), and ¹³C NMR (125 MHz, CDCl₃), see Table 1; HRESIMS m/z 645.4726 [M + Na]⁺ (calcd for C₃₇H₆₆NaO₇, 645.4726).

Preparation of the (R)- and (S)-MPA Ester Derivatives of 1 and 2

In a 25-mL round-bottom flask, 5.00 mg *R*-(–)-α-methoxy-phenylacetic acid ((*R*)-MPA) was dissolved in 5 mL of CH₂Cl₂ and 15 mg oxalyl chloride. Several drops of dimethylformamide were added to the reaction system as a catalyst. The reactants were mixed with a magnetic stir bar in an ice bath for 1 h to obtain 4.98 mg *R*-(–)-α-methoxy-phenylacetyl chloride (91% yield). The in-NMR tube reaction was carried out to prepare the MPA ester derivatives.²² The selected acetogenin (0.2 mg) dissolved in CDCl₃ was transferred to a clean NMR tube and the solvent was completely evaporated. *R*-(–)-α-methoxy-phenylacetyl chloride (0.5 mg) was dissolved in CDCl₃ (0.5 mL) and added to the NMR tube immediately under an N₂ gas flow, and the NMR tube was shaken carefully to mix the acetogenin and MPA chloride. The reaction NMR tube was kept at room temperature under N₂ for 6 hours to form the (*R*)-MPA ester and was then analyzed by ¹H

NMR spectroscopy. The (*S*)-MPA ester of the acetogenin was prepared from (*S*)-MPA by the same method.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This project was supported by the Fogarty International Center, the National Cancer Institute, the National Science Foundation, the National Heart, Lung and Blood Institute, the National Institute of Mental Health, the Office of Dietary Supplements, and the Office of the Director of NIH, under Cooperative Agreement U01 TW000313 with the International Cooperative Biodiversity Groups. This project was also supported by the National Research Initiative of the Cooperative State Research, Education and Extension Service, USDA, Grant #2008-35621-04732. These supports are gratefully acknowledged. This work was also supported by the National Science Foundation under Grant no. CHE-0619382 for purchase of the Bruker Avance 600 NMR spectrometer and Grant no. CHE-0722638 for the purchase of the Agilent 6220 mass spectrometer. We thank Mr. B. Bebout for obtaining the mass spectra and Dr. Hugo Azurmendi for assistance with the NMR spectra. We also thank Dr. Thierry Deroin, a specialist on the Annonaceae family, for confirming the determination of the collection. Field work essential for this project was conducted under a collaborative agreement between the Missouri Botanical Garden and the Parc Botanique et Zoologique de Tsimbazaza and a multilateral agreement between the ICBG partners, including the Centre National d'Applications des Recherches Pharmaceutiques. We gratefully acknowledge courtesies extended by the Government of Madagascar (Ministère des Eaux et Forêts).

REFERENCES AND NOTES

1. Biodiversity Conservation and Drug Discovery in Madagascar, Part 50. For Part 49, see Pan E, Gorka A, Alumasa J, Slebodnick C, Harinantenaina L, Brodie PJ, Roepe PD, Randrianavo R, Birkinshaw C, Kingston DGI. *J Nat Prod*. 2011; 74:2174–2180. [PubMed: 21995542]
2. Alali FQ, Kaakeh W, Bennett GW, McLaughlin JL. *J Econ Entomol*. 1998; 91:641–9. [PubMed: 9650513]
3. Liu HX, Huang GR, Zhang HM, Wu JR, Yao ZJ. *Bioorg Med Chem Lett*. 2007; 17:3426–30. [PubMed: 17433671]
4. Yuan SS, Chang HL, Chen HW, Kuo FC, Liaw CC, Su JH, Wu YC. *Life Sci*. 2006; 78:869–74. [PubMed: 16154156]
5. Pomper KW, Lowe JD, Crabtree SB, Keller W. *J Agric Food Chem*. 2009; 57:8339–43. [PubMed: 19711911]
6. McLaughlin JL. *J Nat Prod*. 2008; 71:1311–1321. [PubMed: 18598079]
7. Parmar VS, Tyagi OD, Malhotra A, Singh SK, Bisht KS, Jain R. *Nat Prod Rep*. 1994; 11:219–24. [PubMed: 15209131]
8. Yang XN, Chen HS. *Yaoxue Shijian Zazhi*. 2009; 27:81–83.
9. Padma P, Khosa RL, Sahai M. *Indian J Nat Prod*. 1996; 12:3–21.
10. Jolad SD, Hoffmann JJ, Schram KH, Cole JR, Tempesta MS, Kriek GR, Bates RB. *J Org Chem*. 1982; 47:3151–3153.
11. Missouri Botanical Garden, St. Louis, U.S.A. and Missouri Botanical Garden, Madagascar Research and Conservation Program, Antananarivo, Madagascar. [accessed November 16, 2011] Madagascar Catalogue. Catalogue of the Vascular Plants of Madagascar. 2011. <http://www.tropicos.org/project/mada>
12. Liaw CC, Chang FR, Chen YY, Chiu HF, Wu MJ, Wu YC. *J Nat Prod*. 1999; 62:1613–1617. [PubMed: 10654411]
13. Hui YH, Rupprecht JK, Liu YM, Anderson JE, Smith DL, Chang CJ, McLaughlin JL. *J Nat Prod*. 1989; 52:463–477. [PubMed: 2778448]
14. Santos LARD, Boaventura MAD, Pimenta LPS. *Biochem System Ecol*. 2006; 34:78–82.
15. Chang FR, Wu YC. *J Nat Prod*. 2001; 64:925–931. [PubMed: 11473425]
16. Lima LARS, Pimenta LPS, Boaventura MAD. *Food Chem*. 2010; 122:1129–1138.

17. Fang XP, Gu ZM, Rieser MJ, Hui YH, McLaughlin JL, Nonfon M, Lieb F, Moeschler HF, Wendisch D. *J Nat Prod.* 1993; 56:1095–100. [PubMed: 8377016]
18. Queiroz EF, Roblot F, Cavé A, Hocquemiller R, Serani L, Laprévote O, Paulo MdQ. *J Nat Prod.* 1999; 62:710–713. [PubMed: 10346951]
19. Gu ZM, Fang XP, Zeng L, Kozlowski JF, McLaughlin JL. *Bioorg Med Chem Lett.* 1994; 4:473–478.
20. Rieser MJ, Hui YH, Rupprecht JK, Kozlowski JF, Wood KV, McLaughlin JL, Hanson PR, Zhuang Z, Hoye TR. *J Am Chem Soc.* 1992; 114:10203–10213.
21. Latypov SK, Seco JM, Quinoa E, Riguera R. *J Org Chem.* 1996; 61:8569–8577.
22. Su BN, Park EJ, Mbawambo ZH, Santarsiero BD, Mesecar AD, Fong HHS, Pezzuto JM, Kinghorn AD. *J Nat Prod.* 2002; 65:1278–1282. [PubMed: 12350147]
23. Zhao GX, Gu ZM, Zeng L, Chao JF, Kozlowski JF, Wood KV, McLaughlin JL. *Tetrahedron.* 1995; 51:7149–7160.
24. Raynaud S, Fourneau C, Hocquemiller R, Sévenet T, Hadi HA, Cavé A. *Phytochemistry.* 1997; 46:321–326.
25. Zhou GX, Chen RY, Zhang YJ, Yu DQ. *J Nat Prod.* 2000; 63:1201–1204. [PubMed: 11000019]
26. Hopp DC, Zeng L, Gu ZM, McLaughlin JL. *J Nat Prod.* 1996; 59:97–99. [PubMed: 8991957]
27. Lima LARS, Pimenta LPS, Boaventura MAD. *Planta Med.* 2009; 75:80, 83. [PubMed: 19039734]
28. Chahboune N, Barrachina I, Royo I, Romero V, Sáez J, Tormo JR, De Pedro N, Estornell E, Zafra-Polo MC, Peláez F, Cortes D. *Bioorg Med Chem.* 2006; 14:1089–1094. [PubMed: 16242335]
29. Hopp DC, Alali FQ, Gu Z-m, McLaughlin JL. *Bioorg Med Chem.* 1998; 6:569–575. [PubMed: 9629470]
30. Royo I, DePedro N, Estornell E, Cortes D, Pelaez F, Tormo JR. *Oncology Res.* 2003; 13:521–8.
31. Gonzalez-Coloma A, Guadano A, de Ines C, Martinez-Diaz R, Cortes D. *Z Naturforsch C.* 2002; 57:1028–34. [PubMed: 12562089]
32. Abe M, Kenmochi A, Ichimaru N, Hamada T, Nishioka T, Miyoshi H. *Bioorg Med Chem Lett.* 2004; 14:779–82. [PubMed: 14741288]
33. Kojima N, Tanaka T. *Molecules.* 2009; 14:3621–61. [PubMed: 19783948]
34. Rakotonandrasana, S. [accessed November 16, 2011] Missouri Botanical Garden, St. Louis, U.S.A. and Missouri Botanical Garden, Madagascar Research and Conservation Program, Antananarivo, Madagascar. Madagascar Catalogue. <http://www.tropicos.org/Specimen/2822281>
35. Cao S, Brodie PJ, Miller JS, Randrianaivo R, Ratovoson F, Birkinshaw C, Andriantsiferana R, Rasamison VE, Kingston DGI. *J Nat Prod.* 2007; 70:679–681. [PubMed: 17323994]
36. Pan E, Harinantenaina L, Brodie PJ, Callmender M, Rakotonandrasana S, Rakotobe E, Rasamison VE, TenDyke K, Shen Y, Suh EM, Kingston DGI. *Bioorg Med Chem.* 2011; 19:422–428. [PubMed: 21159516]

Table 1NMR Spectroscopic Data for **1** and **2** in CDCl₃ (500 MHz)

1			2	
position	δ_{H} (J, Hz)	δ_{C}, type	δ_{H} (J, Hz)	δ_{C}, type
1	-	174.2, C	-	174.0, C
2	-	134.6, C	-	133.9, C
3a	2.26 tdd (7.2, 1.6, 1.6)	25.1, CH ₂	2.37 dtd (15.2, 7.6, 1.6)	21.6, CH ₂
3b	2.26 tdd (7.2, 1.6, 1.6)		2.51 dtd (15.2, 7.6, 1.6)	
4	1.54 m	27.6, CH ₂	1.65 m	35.4, CH ₂
5	1.25 m	29.6–29.9, CH ₂	3.60 m	70.9, CH
6	1.25 m	25.4, CH ₂	1.39 m	37.6, CH ₂
7	1.39–1.42 m	37.7, CH ₂	1.48 m	26.1, CH ₂
8	3.60 m	72.1, CH	1.26 m	29.6–29.8, CH ₂
9	1.39–1.42 m	37.4, CH ₂	1.26 m	29.6–29.8, CH ₂
10	1.25 m	22.2, CH ₂	1.26 m	29.6–29.8, CH ₂
11	1.39–1.42 m	32.7, CH ₂	1.26 m	29.6–29.8, CH ₂
12	3.87 m	71.6, CH	1.48 m	25.6, CH ₂
13	3.83 m	83.0, CH	1.41 m	32.5, CH ₂
14a	1.62 m	28.6, CH ₂	3.86 m	71.4, CH
14b	1.87 m			
15a	1.62 m	29.1, CH ₂	3.83 m	82.9, CH
15b	1.87 m			
16a	3.93 m	82.5, CH	1.67 m	28.4, CH ₂
16b			1.82 m	
17a	3.91 m	82.8, CH	1.67 m	29.0, CH ₂
17b			1.82 m	
18a	1.60 m	29.1, CH ₂	3.93 m	82.4, CH
18b	1.97 m			
19a	1.60 m	28.6, CH ₂	3.91 m	82.6, CH
19b	1.97 m			
20a	3.84 m	83.5, CH	1.61 m	29.1, CH ₂
20b			1.95 m	
21a	3.39 m	74.4, CH	1.61 m	29.4, CH ₂
21b			1.95 m	
22	1.39–1.42 m	33.5, CH ₂	3.84 m	83.3, CH
23	1.25 m	25.9, CH ₂	3.37 m	74.2, CH
24	1.25 m	29.6–29.9, CH ₂	1.41 m	33.5, CH ₂
25	1.25 m	29.6–29.9, CH ₂	1.48 m	25.7, CH ₂
26–31	1.25 m	29.6–29.9, CH ₂	1.26 m	29.6–29.8, CH ₂
32	1.25 m	32.1, CH ₂	1.26 m	32.00, CH ₂

1			2	
position	δ_{H} (J, Hz)	δ_{C} , type	δ_{H} (J, Hz)	δ_{C} , type
33	1.25 m	22.8, CH ₂	1.26 m	22.8, CH ₂
34	0.88 t (6.9)	14.3, CH ₃	0.86 t (6.9)	14.2, CH ₃
35	6.98 td (1.5, 1.5)	149.1, CH	7.05 td (1.5, 1.5)	149.3, CH
36	4.98 qdd (6.8, 1.5, 1.5)	77.6, CH	5.01 qd (6.8, 1.5)	77.7, CH
37	1.41, d (6.8)	19.4, CH ₃	1.40 d (6.9)	19.3, CH ₃

Table 2Antiproliferative Activities of Compounds **1** and **2**

Compound	IC ₅₀ (μM)		
	A2780	A2058	H522
1	6.4	6.6	<10
2	8.8	7.2	<10
Paclitaxel	0.02	ND	ND